Company Product Description Indication Status
Phase I
Bicycle Therapeutics plc, of Cambridge, U.K. BT-1718 Peptide-toxin conjugate targeting MT1-MMP  Advanced solid tumors Completed dose escalation, established 20 mg/m2 administered once weekly as the recommended dose for phase II; 1 of 24 patients had a partial response
Bicycle Therapeutics plc, of Cambridge, U.K. BT-5528 Peptide-toxin conjugate targeting EphA2 Advanced solid tumors associated with EphA2 expression Second cohort of patients completed dosing; drug appeared well-tolerated with manageable adverse events
Bicycle Therapeutics plc, of Cambridge, U.K. BT-8009   Peptide-toxin conjugate targeting Nectin-4 Advanced solid tumors associated with Nectin-4 expression Plans to start clinical trial this year, subject to impact of COVID-19 pandemic
Boston Biomedical Inc., of Cambridge, Mass. TP-3654  PIM kinase inhibitor Intermediate-2 and high-risk primary or secondary myelofibrosis First patient treated in study designed to determine the maximum tolerated dose and recommended phase II dose; study will also measure pharmacokinetics, preliminary clinical activity and safety
Crinetics Pharmaceuticals Inc., of San Diego CRN-01941  Somatostatin sst2 receptor agonist Healthy volunteers Drug wasn't more active than paltusotine, so discontinuing development of CRN-01941 to focus on paltusotine
Precision Biosciences Inc., of Durham, N.C. PBCAR-20A Allogeneic anti-CD20 CAR T Relapsed/refractory non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia or R/R small lymphocytic lymphoma  Started patient dosing in the dose-escalation and dose-expansion study
Quantum Genomics SAS, of Paris QGC-001 Aminopeptidase A inhibitor End-stage renal failure All patients with renal failure enrolled and treated; half of healthy volunteers completed the trial but enrollment temporarily halted due to COVID-19; in order to limit impact to trial, company will conduct interim analysis 
Phase II
Bellus Health Inc., of Laval, Quebec BLU-5937 P2X3 receptor antagonist Refractory chronic cough Completed dosing of 52 patients in the Relief study; 16 patients dropped out of the study, including 13 due to COVID-19 pandemic or early termination of the trial; data expected in mid-2020
Can-Fite Biopharma Ltd., of Petach Tikva, Israel Namodenoson Targets A3 adenosine receptor Nonalcoholic fatty liver disease 36.8% and 23.8% of patients taking the 25-mg and 12.5-mg doses, respectively, reached ALT normalization after 12 weeks of treatment and 4 weeks of follow-up, compared to 10% of the placebo group (p=0.038 for 25 mg vs. placebo); liver fat and liver stiffness decreased for both doses throughout the study period; serum adiponectin levels increased by 220 ng/mL and 539 ng/mL in the 25-mg and 12.5-mg groups, respectively (p=0.03)
Crinetics Pharmaceuticals Inc., of San Diego Paltusotine (CRN-00808) Somatostatin sst2 receptor agonist Acromegaly  Interim results from the first 13 patients in the Acrobat Edge study showed switching from octreotide or lanreotide depot monotherapy to paltusotine maintained patients' IGF-1 levels with a mean change from baseline of -0.015 x upper limit of the normal range; data for all patients expected in the fourth quarter of 2020
Inventiva SAS, of Daix, France Lanifibranor Targets PPAR Nonalcoholic fatty liver disease Recruitment and screening of new patients suspended due to COVID-19; patients already included to continue receiving treatment as per protocol
Kalvista Pharmaceuticals Inc., of Cambridge, Mass. KVD-900  Plasma kallikrein inhibitor Hereditary angioedema Data from study delayed due to COVID-19; expects data in second half of 2020 if participants are able to resume their activity during the second quarter of 2020
Kazia Therapeutics Ltd., of Sydney Paxalisib  Inhibitor of the PI3K/AKT/mTOR pathway Glioblastoma Interim analysis of 9 patients in the escalation cohort showed median overall survival of 17.7 months; progression-free survival of 30 patients in dose-escalation and expansion cohorts was 8.5 months; more data expected in the second half of 2020 with final data in first half of 2021
Seneca Biopharma Inc., of Germantown, Md. NSI-566 Neural stem cells Chronic ischemic stroke Follow-up assessments completed on 60% of the patients; data expected in the second half of 2020
Vaccinex Inc., of Rochester, N.Y. Pepinemab Monoclonal antibody targeting SEMA4D Huntington’s disease In cohort A with 19 patients, estimated difference between drug and placebo for the mean fluorodeoxyglucose uptake as measured by positron emission tomography was 0.78 (p=0.025); 200 of 265 patients in cohort B have completed the 18 months of treatment and a safety follow-up
Phase III
AB Science SA, of  Paris Masitinib Selective tyrosine kinase inhibitor Mastocytosis Confirmatory study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months
AB Science SA, of  Paris Masitinib Selective tyrosine kinase inhibitor Amyotrophic lateral sclerosis Confirmatory study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments